Janux Therapeutics (JANX) EBIT (2020 - 2026)
Janux Therapeutics (JANX) reported EBIT of -$34.2 million for Q1 2026, up 1.96% year-over-year from -$33.6 million in Q1 2025, and up 19.31% quarter-over-quarter from -$42.4 million in Q4 2025.
Janux Therapeutics (JANX) EBIT (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 7 years of EBIT data on file, last reported at -$34.2 million in Q1 2026.
- EBIT for Q1 2026 came in at -$34.2 million, up 1.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$157.0 million (down 38.21% YoY), and the FY2025 annual result was -$157.7 million, down 59.51% from the prior year.
- EBIT grew to -$34.2 million in Q1 2026 per JANX's latest filing, from -$42.4 million in the prior quarter.
- Over five years, EBIT peaked at -$13.5 million in Q1 2022 and troughed at -$45.1 million in Q2 2025.
- A 5-year average of -$25.3 million and a median of -$20.3 million in 2023 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2024: EBIT tumbled 492.91% in 2022, then jumped 33.38% in 2024.
- A 5-year view of EBIT shows it stood at -$18.3 million in 2022, then rose by 11.66% to -$16.1 million in 2023, then sank by 79.85% to -$29.0 million in 2024, then plunged by 46.1% to -$42.4 million in 2025, then grew by 19.31% to -$34.2 million in 2026.
- Business Quant data shows JANX's EBIT at -$34.2 million in Q1 2026, -$42.4 million in Q4 2025, and -$35.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Janux Therapeutics | 892.99 Mn | 892.99 Mn | - | -34.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.21 Mn |
| Dec 31, 2025 | -42.40 Mn |
| Sep 30, 2025 | -35.25 Mn |
| Jun 30, 2025 | -45.12 Mn |
| Mar 31, 2025 | -34.90 Mn |
| Dec 31, 2024 | -29.02 Mn |
| Sep 30, 2024 | -35.84 Mn |
| Jun 30, 2024 | -13.82 Mn |
| Mar 31, 2024 | -20.16 Mn |
| Dec 31, 2023 | -16.14 Mn |
| Sep 30, 2023 | -15.81 Mn |
| Jun 30, 2023 | -20.75 Mn |
| Mar 31, 2023 | -20.28 Mn |
| Dec 31, 2022 | -18.27 Mn |
| Sep 30, 2022 | -18.02 Mn |
| Jun 30, 2022 | -17.26 Mn |
| Mar 31, 2022 | -13.54 Mn |
| Dec 31, 2021 | -13.49 Mn |
| Sep 30, 2021 | -10.90 Mn |
| Jun 30, 2021 | -6.25 Mn |